Agreements of this type fulfil the requirements of the WHO Code: They help individual health workers move to countries of destination, they increase the number of skilled workers and improve health systems in countries of origin, and they manage migration in an ethical and sustainable way. They deserve to be piloted, tested, appropriately modified, and scaled.
CGD Policy Blogs
A lot of recent discussions focus on how to expand COVID-19 vaccine manufacturing capacity in low- and middle-income countries (LMICs). The conversations highlight the importance of technology transfer and the capability of the tech transfer receiving sites (the facilities in these countries that would then produce vaccines locally), including having specialized equipment and personnel.
More than Oxygen Supply: How to Make the Current Global Fund COVID-19 Response Mechanism a Success for Patients
The global COVID-19 pandemic has highlighted the pressing need to improve oxygen supplies around the world. In this blog, we highlight key objectives that countries need to consider in their funding applications for support from the CRM for the successful scale up of oxygen and critical care.
Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis
Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.
Effective vaccines are developed through collaboration between governments, publicly funded research universities and for-profit pharmaceutical companies. But the incentives to produce the doses can often leave out lower-income countries.
As governments worldwide increase their COVID-19 vaccination coverage, COVID-19 vaccination certificates (CVCs) are making headlines as a possible answer to the question of how to reopen economies safely. While countries like Israel and Estonia are well advanced in introducing CVCs, developing countries, as with their vaccination rates, are further behind. In especially interconnected developing regions like Southeast Asia, CVCs present unprecedented collaboration challenges, including that of coordination and trust.
The Philippines has been hit hard by the COVID-19 pandemic, with 1.06 million confirmed cases and 17,500 deaths as of May 3, 2021. These numbers are likely just the tip of the iceberg as the pandemic’s indirect health effects have largely gone unmeasured.
I am very pleased to welcome Javier Guzman as the new Director of CGD’s Global Health Policy Program and a Senior Policy Fellow.
In 2003, an estimated 3 million people died of HIV/AIDS globally. In May of that year, galvanized by the growing number of preventable deaths given the availability of an effective medicine, the President’s Emergency Plan for AIDS Relief—PEPFAR—was signed into law.